Literature DB >> 31269811

Quantitative Myocardial Perfusion in Fabry Disease.

Kristopher D Knott1,2, Joao B Augusto1,2, Sabrina Nordin1,2, Rebecca Kozor3, Claudia Camaioni2, Hui Xue4, Rebecca K Hughes1,2, Charlotte Manisty1,2, Louise A E Brown5, Peter Kellman4, Uma Ramaswami6, Derralyn Hughes6, Sven Plein5, James C Moon1,2.   

Abstract

BACKGROUND: Fabry disease (FD) is an X-linked lysosomal storage disease resulting in tissue accumulation of sphingolipids. Key myocardial processes that lead to adverse outcomes in FD include storage, hypertrophy, inflammation, and fibrosis. These are quantifiable by multiparametric cardiovascular magnetic resonance. Recent developments in cardiovascular magnetic resonance perfusion mapping allow rapid in-line perfusion quantification permitting broader clinical application, including the assessment of microvascular dysfunction. We hypothesized that microvascular dysfunction in FD would be associated with storage, fibrosis, and edema.
METHODS: A prospective, observational study of 44 FD patients (49 years, 43% male, 24 [55%] with left ventricular hypertrophy [LVH]) and 27 healthy controls with multiparametric cardiovascular magnetic resonance including vasodilator stress perfusion mapping. Myocardial blood flow (MBF) was measured and its associations with other processes investigated.
RESULTS: Compared with LVH- FD, LVH+ FD had higher left ventricular ejection fraction (73% versus 68%), more late gadolinium enhancement (85% versus 15%), and a lower stress MBF (1.76 versus 2.36 mL/g per minute). The reduction in stress MBF was more pronounced in the subendocardium than subepicardium. LVH- FD had lower stress MBF than controls (2.36 versus 3.00 mL/g per minute; P=0.002). Across all FD, late gadolinium enhancement and low native T1 were independently associated with reduced stress MBF. On a per-segment basis, stress MBF was independently associated with wall thickness, T2, extracellular volume fraction, and late gadolinium enhancement.
CONCLUSIONS: FD patients have reduced perfusion, particularly in the subendocardium with greater reductions with LVH, storage, edema, and scar. Perfusion is reduced even without LVH suggesting it is an early disease marker.

Entities:  

Keywords:  cardiomyopathies; edema; fibrosis; lysosomal storage diseases

Mesh:

Year:  2019        PMID: 31269811      PMCID: PMC8323709          DOI: 10.1161/CIRCIMAGING.119.008872

Source DB:  PubMed          Journal:  Circ Cardiovasc Imaging        ISSN: 1941-9651            Impact factor:   7.792


  42 in total

1.  Improvement of impaired coronary vasodilator reserve in hypertensive patients by low-dose ACE inhibitor/diuretic therapy: a pilot PET study.

Authors:  Jean-Jacques Mourad; Olivier Hanon; Jean-Robert Deverre; Paolo G Camici; Philippe Sellier; Denis Duboc; Michel E Safar
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2003-06       Impact factor: 1.636

2.  Perindopril and indapamide reverse coronary microvascular remodelling and improve flow in arterial hypertension.

Authors:  Danilo Neglia; Enza Fommei; Anabel Varela-Carver; Massimiliano Mancini; Sergio Ghione; Massimo Lombardi; Patrizia Pisani; Howard Parker; Giulia D'amati; Luigi Donato; Paolo G Camici
Journal:  J Hypertens       Date:  2011-02       Impact factor: 4.844

3.  Coronary vasodilation is impaired in both hypertrophied and nonhypertrophied myocardium of patients with hypertrophic cardiomyopathy: a study with nitrogen-13 ammonia and positron emission tomography.

Authors:  P Camici; G Chiriatti; R Lorenzoni; R C Bellina; R Gistri; G Italiani; O Parodi; P A Salvadori; N Nista; L Papi
Journal:  J Am Coll Cardiol       Date:  1991-03-15       Impact factor: 24.094

4.  Gadgetron: an open source framework for medical image reconstruction.

Authors:  Michael Schacht Hansen; Thomas Sangild Sørensen
Journal:  Magn Reson Med       Date:  2012-07-12       Impact factor: 4.668

5.  Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy.

Authors:  Beth L Thurberg; Helmut Rennke; Robert B Colvin; Steven Dikman; Ronald E Gordon; A Bernard Collins; Robert J Desnick; Michael O'Callaghan
Journal:  Kidney Int       Date:  2002-12       Impact factor: 10.612

6.  Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy.

Authors:  Franco Cecchi; Iacopo Olivotto; Roberto Gistri; Roberto Lorenzoni; Giampaolo Chiriatti; Paolo G Camici
Journal:  N Engl J Med       Date:  2003-09-11       Impact factor: 91.245

7.  Splenic Switch-off: A Tool to Assess Stress Adequacy in Adenosine Perfusion Cardiac MR Imaging.

Authors:  Charlotte Manisty; David P Ripley; Anna S Herrey; Gabriella Captur; Timothy C Wong; Steffen E Petersen; Sven Plein; Charles Peebles; Erik B Schelbert; John P Greenwood; James C Moon
Journal:  Radiology       Date:  2015-04-29       Impact factor: 11.105

8.  Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume: A consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular Imaging (EACVI).

Authors:  Daniel R Messroghli; James C Moon; Vanessa M Ferreira; Lars Grosse-Wortmann; Taigang He; Peter Kellman; Julia Mascherbauer; Reza Nezafat; Michael Salerno; Erik B Schelbert; Andrew J Taylor; Richard Thompson; Martin Ugander; Ruud B van Heeswijk; Matthias G Friedrich
Journal:  J Cardiovasc Magn Reson       Date:  2017-10-09       Impact factor: 5.364

9.  Fully automated, inline quantification of myocardial blood flow with cardiovascular magnetic resonance: repeatability of measurements in healthy subjects.

Authors:  Louise A E Brown; Sebastian C Onciul; David A Broadbent; Kerryanne Johnson; Graham J Fent; James R J Foley; Pankaj Garg; Pei G Chew; Kristopher Knott; Erica Dall'Armellina; Peter P Swoboda; Hui Xue; John P Greenwood; James C Moon; Peter Kellman; Sven Plein
Journal:  J Cardiovasc Magn Reson       Date:  2018-07-09       Impact factor: 5.364

10.  Quantitative myocardial perfusion in coronary artery disease: A perfusion mapping study.

Authors:  Kristopher D Knott; Claudia Camaioni; Anantharaman Ramasamy; Joao A Augusto; Anish N Bhuva; Hui Xue; Charlotte Manisty; Rebecca K Hughes; Louise A E Brown; Rajiv Amersey; Christos Bourantas; Peter Kellman; Sven Plein; James C Moon
Journal:  J Magn Reson Imaging       Date:  2019-01-25       Impact factor: 4.813

View more
  10 in total

1.  Coronary microvascular disease in hypertrophic and infiltrative cardiomyopathies.

Authors:  Andreas A Giannopoulos; Ronny R Buechel; Philipp A Kaufmann
Journal:  J Nucl Cardiol       Date:  2022-08-01       Impact factor: 3.872

2.  The Prognostic Significance of Quantitative Myocardial Perfusion: An Artificial Intelligence-Based Approach Using Perfusion Mapping.

Authors:  Kristopher D Knott; Andreas Seraphim; Joao B Augusto; Hui Xue; Liza Chacko; Nay Aung; Steffen E Petersen; Jackie A Cooper; Charlotte Manisty; Anish N Bhuva; Tushar Kotecha; Christos V Bourantas; Rhodri H Davies; Louise A E Brown; Sven Plein; Marianna Fontana; Peter Kellman; James C Moon
Journal:  Circulation       Date:  2020-02-14       Impact factor: 29.690

Review 3.  T2 mapping in myocardial disease: a comprehensive review.

Authors:  Aaron T O'Brien; Katarzyna E Gil; Juliet Varghese; Orlando P Simonetti; Karolina M Zareba
Journal:  J Cardiovasc Magn Reson       Date:  2022-06-06       Impact factor: 6.903

4.  Quantification of myocardial deformation in patients with Fabry disease by cardiovascular magnetic resonance feature tracking imaging.

Authors:  Lei Zhao; Chen Zhang; Jie Tian; Madiha Saiedi; Chenyao Ma; Ning Li; Fang Fang; Xiaohai Ma; Joseph Selvanayagam
Journal:  Cardiovasc Diagn Ther       Date:  2021-02

Review 5.  Fabry Disease and the Heart: A Comprehensive Review.

Authors:  Olga Azevedo; Filipa Cordeiro; Miguel Fernandes Gago; Gabriel Miltenberger-Miltenyi; Catarina Ferreira; Nuno Sousa; Damião Cunha
Journal:  Int J Mol Sci       Date:  2021-04-23       Impact factor: 5.923

Review 6.  Cardiac Imaging in Anderson-Fabry Disease: Past, Present and Future.

Authors:  Roberta Esposito; Ciro Santoro; Giulia Elena Mandoli; Vittoria Cuomo; Regina Sorrentino; Lucia La Mura; Maria Concetta Pastore; Francesco Bandera; Flavio D'Ascenzi; Alessandro Malagoli; Giovanni Benfari; Antonello D'Andrea; Matteo Cameli
Journal:  J Clin Med       Date:  2021-05-06       Impact factor: 4.241

7.  The myocardial phenotype of Fabry disease pre-hypertrophy and pre-detectable storage.

Authors:  João B Augusto; Nicolas Johner; Dipen Shah; Sabrina Nordin; Kristopher D Knott; Stefania Rosmini; Clement Lau; Mashael Alfarih; Rebecca Hughes; Andreas Seraphim; Ravi Vijapurapu; Anish Bhuva; Linda Lin; Natalia Ojrzyńska; Tarekegn Geberhiwot; Gabriella Captur; Uma Ramaswami; Richard P Steeds; Rebecca Kozor; Derralynn Hughes; James C Moon; Mehdi Namdar
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2021-06-22       Impact factor: 6.875

8.  Inline perfusion mapping provides insights into the disease mechanism in hypertrophic cardiomyopathy.

Authors:  Claudia Camaioni; Kristopher D Knott; Joao B Augusto; Andreas Seraphim; Stefania Rosmini; Fabrizio Ricci; Redha Boubertakh; Hui Xue; Rebecca Hughes; Gaby Captur; Luis Rocha Lopes; Louise Anne Elizabeth Brown; Charlotte Manisty; Steffen Erhard Petersen; Sven Plein; Peter Kellman; Saidi A Mohiddin; James C Moon
Journal:  Heart       Date:  2019-12-10       Impact factor: 5.994

9.  Cardiovascular magnetic resonance native T2 and T2* quantitative values for cardiomyopathies and heart transplantations: a systematic review and meta-analysis.

Authors:  G J H Snel; M van den Boomen; L M Hernandez; C T Nguyen; D E Sosnovik; B K Velthuis; R H J A Slart; R J H Borra; N H J Prakken
Journal:  J Cardiovasc Magn Reson       Date:  2020-05-11       Impact factor: 5.364

10.  Myocardial Perfusion Defects in Hypertrophic Cardiomyopathy Mutation Carriers.

Authors:  Rebecca K Hughes; Claudia Camaioni; João B Augusto; Kristopher Knott; Ellie Quinn; Gabriella Captur; Andreas Seraphim; George Joy; Petros Syrris; Perry M Elliott; Saidi Mohiddin; Peter Kellman; Hui Xue; Luis R Lopes; James C Moon
Journal:  J Am Heart Assoc       Date:  2021-07-27       Impact factor: 5.501

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.